{
    "clinical_study": {
        "@rank": "70469", 
        "arm_group": {
            "arm_group_label": "Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 3. Patients also receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on day 1. Treatment repeats every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of CPI-613 when given together\n      with combination chemotherapy in treating patients with metastatic pancreatic cancer. Drugs\n      used in chemotherapy, CPI-613, leucovorin calcium, fluorouracil, irinotecan hydrochloride,\n      and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing\n      the cells or by stopping them from dividing."
        }, 
        "brief_title": "CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer", 
        "condition": [
            "Acinar Cell Adenocarcinoma of the Pancreas", 
            "Duct Cell Adenocarcinoma of the Pancreas", 
            "Recurrent Pancreatic Cancer", 
            "Stage IV Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms", 
                "Carcinoma, Acinar Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerated dose (MTD) of CPI-613 (6,8-bis[benzylthio]octanoic\n      acid), when used in combination with modified leucovorin calcium, fluorouracil, irinotecan\n      hydrochloride, and oxaliplatin (mFOLFIRINOX), in patients with metastatic pancreatic cancer.\n\n      SECONDARY OBJECTIVES:\n\n      I. To assess the safety of CPI-613/mFOLFIRINOX combination in patients with metastatic\n      pancreatic cancer.\n\n      II. To collect tissue for future genomic analyses. III. To obtain preliminary data on\n      efficacy of treatment with CPI-613/mFOLFIRINOX.\n\n      OUTLINE: This is a dose-escalation study of 6,8-bis(benzylthio)octanoic acid.\n\n      Patients receive 6,8-bis(benzylthio)octanoic acid intravenously (IV) over 2 hours on days 1\n      and 3. Patients also receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2\n      hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46\n      hours on day 1. Treatment repeats every 2 weeks for 6 months in the absence of disease\n      progression or unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically and cytologically confirmed metastatic pancreatic adenocarcinoma\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status being 0-1\n\n          -  Expected survival > 2 months\n\n          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not\n             surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine\n             device [IUD], oral contraceptive or double barrier device) during the study, and must\n             have a negative serum or urine pregnancy test within 1 week prior to treatment\n             initiation\n\n          -  Fertile men must practice effective contraceptive methods during the study, unless\n             documentation of infertility exists\n\n          -  At least 2 weeks must have elapsed from any prior surgery or hormonal therapy\n\n          -  Granulocyte count >= 1500/mm^3\n\n          -  White blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/L\n\n          -  Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L\n\n          -  Absolute neutrophil count (ANC) >= 1500 cells/mm^3 or >= 1.5 bil/L\n\n          -  Hemoglobin >= 9 g/dL or >= 90 g/L\n\n          -  Aspartate aminotransferase (AST/serum glutamic oxalic transaminase [SGOT]) =< 3 x\n             upper normal limit (UNL), alanine aminotransferase (ALT/serum glutamate pyruvate\n             transaminase [SGPT]) =< 3 x UNL (=< 5 x UNL if liver metastases present)\n\n          -  Bilirubin =< 1.5 x UNL\n\n          -  Serum creatinine =< 2.0 mg/dL or 177 \u00b5mol/L\n\n          -  International normalized ratio or INR must be =< 1.5 unless on therapeutic blood\n             thinners\n\n          -  No evidence of active infection and no serious infection within the past month\n\n          -  Mentally competent, ability to understand and willingness to sign the informed\n             consent form\n\n        Exclusion Criteria:\n\n          -  Endocrine or acinar pancreatic carcinoma\n\n          -  Previous radiotherapy for cerebral metastases, central nervous system (CNS) or\n             epidural tumor\n\n          -  Prior treatment with any chemotherapy for metastatic disease from pancreatic cancer\n\n          -  Patients receiving any other standard or investigational treatment for their cancer,\n             or any other investigational agent for any indication within the past 4 weeks prior\n             to initiation of CPI-613 treatment\n\n          -  Serious medical illness that would potentially increase patients' risk for toxicity\n\n          -  Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g.,\n             active peptic ulcer disease)\n\n          -  Pregnant women, or women of child-bearing potential not using reliable means of\n             contraception (because the teratogenic potential of CPI-613 is unknown)\n\n          -  Lactating females\n\n          -  Fertile men unwilling to practice contraceptive methods during the study period\n\n          -  Life expectancy less than 2 months\n\n          -  Any condition or abnormality which may, in the opinion of the investigator,\n             compromise the safety of patients\n\n          -  Unwilling or unable to follow protocol requirements\n\n          -  Active heart disease including but not limited to symptomatic congestive heart\n             failure, symptomatic coronary artery disease, symptomatic angina pectoris,\n             symptomatic myocardial infarction, or symptomatic congestive heart failure\n\n          -  Patients with a history of myocardial infarction that is < 3 months prior to\n             registration\n\n          -  Evidence of active infection, or serious infection within the past month\n\n          -  Patients with known human immunodeficiency virus (HIV) infection\n\n          -  Patients who have received immunotherapy of any type within the past 4 weeks prior to\n             initiation of CPI-613 treatment\n\n          -  Requirement for immediate palliative treatment of any kind including surgery\n\n          -  Patients that have received a chemotherapy regimen with stem cell support in the\n             previous 6 months\n\n          -  Any condition or abnormality which may, in the opinion of the investigator,\n             compromise the safety of the patient"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835041", 
            "org_study_id": "CCCWFU 57112", 
            "secondary_id": [
                "NCI-2013-00674", 
                "P30CA012197"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)", 
                "description": "Given IV", 
                "intervention_name": "6,8-bis(benzylthio)octanoic acid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "alpha-lipoic acid analogue CPI-613", 
                    "CPI-613"
                ]
            }, 
            {
                "arm_group_label": "Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)", 
                "description": "Given IV", 
                "intervention_name": "oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "1-OHP", 
                    "Dacotin", 
                    "Dacplat", 
                    "Eloxatin", 
                    "L-OHP"
                ]
            }, 
            {
                "arm_group_label": "Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)", 
                "description": "Given IV", 
                "intervention_name": "leucovorin calcium", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CF", 
                    "CFR", 
                    "LV"
                ]
            }, 
            {
                "arm_group_label": "Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)", 
                "description": "Given IV", 
                "intervention_name": "irinotecan hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Campto", 
                    "Camptosar", 
                    "CPT-11", 
                    "irinotecan", 
                    "U-101440E"
                ]
            }, 
            {
                "arm_group_label": "Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)", 
                "description": "Given IV", 
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-fluorouracil", 
                    "5-Fluracil", 
                    "5-FU"
                ]
            }, 
            {
                "arm_group_label": "Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Irinotecan", 
                "Camptothecin", 
                "Leucovorin", 
                "Thioctic Acid", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "contact": {
                "email": "aneal@wakehealth.edu", 
                "last_name": "Amy Neal, RN", 
                "phone": "336-713-6912"
            }, 
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Comprehensive Cancer Center of Wake Forest University"
            }, 
            "investigator": {
                "last_name": "Angela T. Alistar", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status", 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "Angela Alistar", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MTD of 6,8-bis(benzylthio)octanoic acid when used in combination with mFOLFIRINOX determined by dose-limiting toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835041"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Comprehensive Cancer Center of Wake Forest University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Comprehensive Cancer Center of Wake Forest University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}